Preparation, characterization and evaluation of metformin encapsulated in PEGylated magnetic Niosome: For molecular targeted therapy of lung cancer
Subject Areas :
Keywords: Lung cancer, Metformin, Targeted drug delivery system, Magnetic Noisome,
Abstract :
It was proven that metformin (MET), a phytochemical broadly used drug in the treatment of type 2 diabetes and Polycystic ovary syndrome (PCOS), can prevent the growth and reproduction of various human tumors like lung cancer cells. Also, in past studies, it was found that MET shows an excellent anti-cancer effect by diminishing the proliferation and stimulating the apoptosis of various cancerous cells. In this study, in the first stage, we synthesized the PEGylated (polyethylene glycol) magnetic niosome (MNio) nanoparticles (NPs) loaded by MET, in the next stage, we evaluated the reaction of MET on the invasion abilities and migration of the A549 cancer cell line in the in vitro condition to create a novel and targeted drug delivery system. Cytotoxicity assay showed that the growth of A549 cell lines was barricaded by free and PEGylate magnetic niosomal metformin (PEG-M-Nio-MET). It was proven that encapsulation of MET in modified niosome decreases the amount of IC50 in the A549 cell line. Also, RT-PCR results demonstrated that the expression levels of the BCL-2 and BAX were considerably decreased in the A549 cancer cell line with PEG-M-Nio-MET and Nio-MET compared to free MET. It is predicted that the application of encapsulated MET in the modified magnetic niosome could significantly improve the treatment efficiency of human lung cancer.